The addition of BNT111 to cemiplimab-rwlc (Libtayo) led to an objective response rate (ORR) of 18.1% (95% CI, 10.9%-27.4%; P = .0115) in patients with PD-(L)1-relapsed/refractory melanoma, allowing investigators to reject the null hypothesis of…
Phase 2 BNT111/Cemiplimab Data Prove Positive in PD-(L)1-Relapsed/Refractory Melanoma
